APM’s first clinical trial
The APM’s first clinical trial is a 3-1 trial of repurposed drugs that have demonstrated neuroprotective effects in preclinical experiments. As part of the APM’s research, we are assessing their potential to change the way Parkinson’s Disease progresses.
Principal Investigators and sites for APM’s first clinical trial are located in Queensland, Victoria, New South Wales, South Australia and Western Australia.
To qualify for the trial, potential participants must be:
- Male or female aged 25 to 80 (inclusive);
- Diagnosed with Parkinson’s Disease; and
- Stable on dopaminergic Parkinson’s Disease treatment for at least four weeks.
Participants enrolled in the trial will undertake procedures such as:
- Receiving one of the three experimental treatments for Parkinson’s Disease. The three treatments are currently being used for the treatment of other diseases; they are therefore known as “repurposed” medicines. You will receive either one of the repurposed medicines or a placebo (a placebo is a medication with no active ingredients);
- Undertaking a physical examination, measurement of vital signs (including heart rate, temperature, and blood pressure), electrocardiogram (ECG) as well as your weight and height;
- Having standard blood tests (e.g. cell counts, blood chemistry, blood sugars, and a pregnancy test) plus providing a collection of blood, saliva and urine samples for biomarker and genomic research; and
- Completing a number of Parkinson’s Disease assessments at each scheduled visit (five visits are required for the trial).
Other APM news
We are excited to announce the chief scientific collaborators of the APM:
- Associate Professor Antony Cooper, Garvan Institute of Medical Research
- Professor Glenda Halliday, University of Sydney
- Dr Nicolas Dzamko, University of Sydney
- Dr Cedric Bardy, SAHMRI and Flinders University
- Assistant Professor Vikram Khurana, Harvard Medical School
- Assistant Professor Jian Peng, University of Illinois
- Associate Professor Justin O’Sullivan, Liggins Institute Auckland
As a reminder, the APM will conduct innovative clinical trials integrated with genomic and biomarker approaches to revolutionise our understanding of Parkinson’s Disease, with the aim of identifying genetic targets for repurposed drugs and drug discovery in Australia, and providing proof-of-principle for a genomic-based precision medicine framework for people living with Parkinson’s Disease.
The APM extends its gratitude to all of our essential services that contribute to Australia’s research effort into COVID-19.
The Australian Parkinson’s Mission Partners
For more information visit:
Phone: 1300 770 577
Australian Parkinson’s Mission Partners
Garvan Institute of Medical Research – garvan.org.au
Shake It Up Australia – shakeitup.org.au
University of Sydney – sydney.edu.au
The Cure Parkinson’s Trust – cureparkinsons.org.uk
Parkinson’s Australia – parkinsons.org.au
The Michael J. Fox Foundation – michaeljfox.org